What is the current valuation of the Mice Model Market as of 2024?

The Mice Model Market was valued at 1.677 USD Billion in 2024. Read More

What is the projected market valuation for the Mice Model Market in 2035?

The market is projected to reach 3.251 USD Billion by 2035. Read More

What is the expected CAGR for the Mice Model Market during the forecast period 2025 - 2035?

The expected CAGR for the Mice Model Market during the forecast period 2025 - 2035 is 6.2%. Read More

Which companies are considered key players in the Mice Model Market?

Key players in the Mice Model Market include Charles River Laboratories, The Jackson Laboratory, and Taconic Biosciences. Read More

What segment of the Mice Model Market had the highest valuation in 2024?

In 2024, the Drug Discovery & Development segment had the highest valuation at 0.8 USD Billion. Read More

How much is the Inbred Mice segment projected to grow by 2035?

The Inbred Mice segment is projected to grow from 0.335 USD Billion in 2024 to 0.65 USD Billion by 2035. Read More

What is the valuation range for the Cryopreservation service in the Mice Model Market?

The Cryopreservation service is valued between 0.3 USD Billion and 0.6 USD Billion. Read More

Which therapeutic area is expected to see significant growth in the Mice Model Market?

The Oncology therapeutic area is expected to grow significantly, with a valuation range of 0.5 USD Billion to 0.95 USD Billion. Read More

What is the projected valuation for the Academic & Research Institutes segment by 2035?

The Academic & Research Institutes segment is projected to reach between 0.5 USD Billion and 0.9 USD Billion by 2035. Read More

What technologies are driving advancements in the Mice Model Market?

Technologies such as CRISPR/CAS9 and Microinjection are driving advancements, with valuations ranging from 0.4 USD Billion to 0.95 USD Billion. Read More

Mice Model Market

ID: MRFR/HC/20372-HCR

128 Pages

Nidhi Mandole

Last Updated: May 15, 2026

Mice Model Market Size, Growth Research Report By Model Type & Service (Model Type, (Inbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Outbred Mice), Service, (Breeding, Cryopreservation, Rederivation, Quarantine and Other Services)), By Technology (CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies), By Therapeutic Area (Oncology, Metabolic Diseases, Immunology, Neurology, Cardiovascular Diseases and Other Therapeutic Diseases), By Application (Drug Discovery & Development, Research Application and Personalized Medicine) – Competitor Industry Analysis and Trends Forecast Till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Model Type (USD Billion)
  1. 4.1.1 Inbred Mice
  2. 4.1.2 Genetically Engineered Mice
  3. 4.1.3 Hybrid/Congenic Mice
  4. 4.1.4 Outbred Mice
2. 4.2 Healthcare, BY Service (USD Billion)
  1. 4.2.1 Breeding
  2. 4.2.2 Cryopreservation
  3. 4.2.3 Rederivation
  4. 4.2.4 Quarantine
  5. 4.2.5 Other services
3. 4.3 Healthcare, BY Technology (USD Billion)
  1. 4.3.1 CRISPR/CAS9
  2. 4.3.2 Microinjection
  3. 4.3.3 Embryonic Stem Cell Injection
  4. 4.3.4 Nuclear Transfer
  5. 4.3.5 Other Technologies
4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Oncology
  2. 4.4.2 Metabolic Diseases
  3. 4.4.3 Immunology
  4. 4.4.4 Neurology
  5. 4.4.5 Cardiovascular Diseases
  6. 4.4.6 Other Therapeutic Diseases
5. 4.5 Healthcare, BY Application (USD Billion)
  1. 4.5.1 Drug Discovery & Development
  2. 4.5.2 Research Application
  3. 4.5.3 Personalized Medicine
6. 4.6 Healthcare, BY End User (USD Billion)
  1. 4.6.1 Pharmaceutical & Biotechnology Companies
  2. 4.6.2 Academic & Research Institutes
  3. 4.6.3 CROS & CDMOS
7. 4.7 Healthcare, BY Region (USD Billion)
  1. 4.7.1 North America
    1. 4.7.1.1 US
    2. 4.7.1.2 Canada
  2. 4.7.2 Europe
    1. 4.7.2.1 Germany
    2. 4.7.2.2 UK
    3. 4.7.2.3 France
    4. 4.7.2.4 Russia
    5. 4.7.2.5 Italy
    6. 4.7.2.6 Spain
    7. 4.7.2.7 Rest of Europe
  3. 4.7.3 APAC
    1. 4.7.3.1 China
    2. 4.7.3.2 India
    3. 4.7.3.3 Japan
    4. 4.7.3.4 South Korea
    5. 4.7.3.5 Malaysia
    6. 4.7.3.6 Thailand
    7. 4.7.3.7 Indonesia
    8. 4.7.3.8 Rest of APAC
  4. 4.7.4 South America
    1. 4.7.4.1 Brazil
    2. 4.7.4.2 Mexico
    3. 4.7.4.3 Argentina
    4. 4.7.4.4 Rest of South America
  5. 4.7.5 MEA
    1. 4.7.5.1 GCC Countries
    2. 4.7.5.2 South Africa
    3. 4.7.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Charles River Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 The Jackson Laboratory (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Taconic Biosciences (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Envigo (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Harlan Laboratories (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Crown Bioscience (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Janvier Labs (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 InVivo Biosystems (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GenOway (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY MODEL TYPE
4. 6.4 US MARKET ANALYSIS BY SERVICE
5. 6.5 US MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA
7. 6.7 US MARKET ANALYSIS BY APPLICATION
8. 6.8 US MARKET ANALYSIS BY END USER
9. 6.9 CANADA MARKET ANALYSIS BY MODEL TYPE
10. 6.10 CANADA MARKET ANALYSIS BY SERVICE
11. 6.11 CANADA MARKET ANALYSIS BY TECHNOLOGY
12. 6.12 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
13. 6.13 CANADA MARKET ANALYSIS BY APPLICATION
14. 6.14 CANADA MARKET ANALYSIS BY END USER
15. 6.15 EUROPE MARKET ANALYSIS
16. 6.16 GERMANY MARKET ANALYSIS BY MODEL TYPE
17. 6.17 GERMANY MARKET ANALYSIS BY SERVICE
18. 6.18 GERMANY MARKET ANALYSIS BY TECHNOLOGY
19. 6.19 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
20. 6.20 GERMANY MARKET ANALYSIS BY APPLICATION
21. 6.21 GERMANY MARKET ANALYSIS BY END USER
22. 6.22 UK MARKET ANALYSIS BY MODEL TYPE
23. 6.23 UK MARKET ANALYSIS BY SERVICE
24. 6.24 UK MARKET ANALYSIS BY TECHNOLOGY
25. 6.25 UK MARKET ANALYSIS BY THERAPEUTIC AREA
26. 6.26 UK MARKET ANALYSIS BY APPLICATION
27. 6.27 UK MARKET ANALYSIS BY END USER
28. 6.28 FRANCE MARKET ANALYSIS BY MODEL TYPE
29. 6.29 FRANCE MARKET ANALYSIS BY SERVICE
30. 6.30 FRANCE MARKET ANALYSIS BY TECHNOLOGY
31. 6.31 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
32. 6.32 FRANCE MARKET ANALYSIS BY APPLICATION
33. 6.33 FRANCE MARKET ANALYSIS BY END USER
34. 6.34 RUSSIA MARKET ANALYSIS BY MODEL TYPE
35. 6.35 RUSSIA MARKET ANALYSIS BY SERVICE
36. 6.36 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
37. 6.37 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
38. 6.38 RUSSIA MARKET ANALYSIS BY APPLICATION
39. 6.39 RUSSIA MARKET ANALYSIS BY END USER
40. 6.40 ITALY MARKET ANALYSIS BY MODEL TYPE
41. 6.41 ITALY MARKET ANALYSIS BY SERVICE
42. 6.42 ITALY MARKET ANALYSIS BY TECHNOLOGY
43. 6.43 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
44. 6.44 ITALY MARKET ANALYSIS BY APPLICATION
45. 6.45 ITALY MARKET ANALYSIS BY END USER
46. 6.46 SPAIN MARKET ANALYSIS BY MODEL TYPE
47. 6.47 SPAIN MARKET ANALYSIS BY SERVICE
48. 6.48 SPAIN MARKET ANALYSIS BY TECHNOLOGY
49. 6.49 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
50. 6.50 SPAIN MARKET ANALYSIS BY APPLICATION
51. 6.51 SPAIN MARKET ANALYSIS BY END USER
52. 6.52 REST OF EUROPE MARKET ANALYSIS BY MODEL TYPE
53. 6.53 REST OF EUROPE MARKET ANALYSIS BY SERVICE
54. 6.54 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
55. 6.55 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
56. 6.56 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
57. 6.57 REST OF EUROPE MARKET ANALYSIS BY END USER
58. 6.58 APAC MARKET ANALYSIS
59. 6.59 CHINA MARKET ANALYSIS BY MODEL TYPE
60. 6.60 CHINA MARKET ANALYSIS BY SERVICE
61. 6.61 CHINA MARKET ANALYSIS BY TECHNOLOGY
62. 6.62 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
63. 6.63 CHINA MARKET ANALYSIS BY APPLICATION
64. 6.64 CHINA MARKET ANALYSIS BY END USER
65. 6.65 INDIA MARKET ANALYSIS BY MODEL TYPE
66. 6.66 INDIA MARKET ANALYSIS BY SERVICE
67. 6.67 INDIA MARKET ANALYSIS BY TECHNOLOGY
68. 6.68 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
69. 6.69 INDIA MARKET ANALYSIS BY APPLICATION
70. 6.70 INDIA MARKET ANALYSIS BY END USER
71. 6.71 JAPAN MARKET ANALYSIS BY MODEL TYPE
72. 6.72 JAPAN MARKET ANALYSIS BY SERVICE
73. 6.73 JAPAN MARKET ANALYSIS BY TECHNOLOGY
74. 6.74 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
75. 6.75 JAPAN MARKET ANALYSIS BY APPLICATION
76. 6.76 JAPAN MARKET ANALYSIS BY END USER
77. 6.77 SOUTH KOREA MARKET ANALYSIS BY MODEL TYPE
78. 6.78 SOUTH KOREA MARKET ANALYSIS BY SERVICE
79. 6.79 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
80. 6.80 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
81. 6.81 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
82. 6.82 SOUTH KOREA MARKET ANALYSIS BY END USER
83. 6.83 MALAYSIA MARKET ANALYSIS BY MODEL TYPE
84. 6.84 MALAYSIA MARKET ANALYSIS BY SERVICE
85. 6.85 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
86. 6.86 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
87. 6.87 MALAYSIA MARKET ANALYSIS BY APPLICATION
88. 6.88 MALAYSIA MARKET ANALYSIS BY END USER
89. 6.89 THAILAND MARKET ANALYSIS BY MODEL TYPE
90. 6.90 THAILAND MARKET ANALYSIS BY SERVICE
91. 6.91 THAILAND MARKET ANALYSIS BY TECHNOLOGY
92. 6.92 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
93. 6.93 THAILAND MARKET ANALYSIS BY APPLICATION
94. 6.94 THAILAND MARKET ANALYSIS BY END USER
95. 6.95 INDONESIA MARKET ANALYSIS BY MODEL TYPE
96. 6.96 INDONESIA MARKET ANALYSIS BY SERVICE
97. 6.97 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
98. 6.98 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
99. 6.99 INDONESIA MARKET ANALYSIS BY APPLICATION
100. 6.100 INDONESIA MARKET ANALYSIS BY END USER
101. 6.101 REST OF APAC MARKET ANALYSIS BY MODEL TYPE
102. 6.102 REST OF APAC MARKET ANALYSIS BY SERVICE
103. 6.103 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
104. 6.104 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
105. 6.105 REST OF APAC MARKET ANALYSIS BY APPLICATION
106. 6.106 REST OF APAC MARKET ANALYSIS BY END USER
107. 6.107 SOUTH AMERICA MARKET ANALYSIS
108. 6.108 BRAZIL MARKET ANALYSIS BY MODEL TYPE
109. 6.109 BRAZIL MARKET ANALYSIS BY SERVICE
110. 6.110 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
111. 6.111 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
112. 6.112 BRAZIL MARKET ANALYSIS BY APPLICATION
113. 6.113 BRAZIL MARKET ANALYSIS BY END USER
114. 6.114 MEXICO MARKET ANALYSIS BY MODEL TYPE
115. 6.115 MEXICO MARKET ANALYSIS BY SERVICE
116. 6.116 MEXICO MARKET ANALYSIS BY TECHNOLOGY
117. 6.117 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
118. 6.118 MEXICO MARKET ANALYSIS BY APPLICATION
119. 6.119 MEXICO MARKET ANALYSIS BY END USER
120. 6.120 ARGENTINA MARKET ANALYSIS BY MODEL TYPE
121. 6.121 ARGENTINA MARKET ANALYSIS BY SERVICE
122. 6.122 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
123. 6.123 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
124. 6.124 ARGENTINA MARKET ANALYSIS BY APPLICATION
125. 6.125 ARGENTINA MARKET ANALYSIS BY END USER
126. 6.126 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODEL TYPE
127. 6.127 REST OF SOUTH AMERICA MARKET ANALYSIS BY SERVICE
128. 6.128 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
129. 6.129 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
130. 6.130 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
131. 6.131 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
132. 6.132 MEA MARKET ANALYSIS
133. 6.133 GCC COUNTRIES MARKET ANALYSIS BY MODEL TYPE
134. 6.134 GCC COUNTRIES MARKET ANALYSIS BY SERVICE
135. 6.135 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
136. 6.136 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
137. 6.137 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
138. 6.138 GCC COUNTRIES MARKET ANALYSIS BY END USER
139. 6.139 SOUTH AFRICA MARKET ANALYSIS BY MODEL TYPE
140. 6.140 SOUTH AFRICA MARKET ANALYSIS BY SERVICE
141. 6.141 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
142. 6.142 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
143. 6.143 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
144. 6.144 SOUTH AFRICA MARKET ANALYSIS BY END USER
145. 6.145 REST OF MEA MARKET ANALYSIS BY MODEL TYPE
146. 6.146 REST OF MEA MARKET ANALYSIS BY SERVICE
147. 6.147 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
148. 6.148 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
149. 6.149 REST OF MEA MARKET ANALYSIS BY APPLICATION
150. 6.150 REST OF MEA MARKET ANALYSIS BY END USER
151. 6.151 KEY BUYING CRITERIA OF HEALTHCARE
152. 6.152 RESEARCH PROCESS OF MRFR
153. 6.153 DRO ANALYSIS OF HEALTHCARE
154. 6.154 DRIVERS IMPACT ANALYSIS: HEALTHCARE
155. 6.155 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
156. 6.156 SUPPLY / VALUE CHAIN: HEALTHCARE
157. 6.157 HEALTHCARE, BY MODEL TYPE, 2024 (% SHARE)
158. 6.158 HEALTHCARE, BY MODEL TYPE, 2024 TO 2035 (USD Billion)
159. 6.159 HEALTHCARE, BY SERVICE, 2024 (% SHARE)
160. 6.160 HEALTHCARE, BY SERVICE, 2024 TO 2035 (USD Billion)
161. 6.161 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
162. 6.162 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
163. 6.163 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
164. 6.164 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
165. 6.165 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
166. 6.166 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
167. 6.167 HEALTHCARE, BY END USER, 2024 (% SHARE)
168. 6.168 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
169. 6.169 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.2.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.2.6 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.3.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.3.6 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.4.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.4.6 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.5.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.5.6 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.6.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.6.6 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.7.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.7.6 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.8.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.8.6 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.9.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.9.6 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.10.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.10.6 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.11.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.11.6 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.12.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.12.6 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.13.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.13.6 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.14.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.14.6 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.15.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.15.6 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.16.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.16.6 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.17.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.17.6 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.18.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.18.6 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.19.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.19.6 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.20.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.20.6 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.21.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.21.6 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.22.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.22.6 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.23.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.23.6 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.24.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.24.6 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.25.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.25.6 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.26.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.26.6 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.27.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.27.6 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.28.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.28.6 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.29.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.29.6 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY MODEL TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY SERVICE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
  5. 7.30.5 BY APPLICATION, 2025-2035 (USD Billion)
  6. 7.30.6 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Model Type (USD Billion, 2025-2035)

Inbred Mice
Genetically Engineered Mice
Hybrid/Congenic Mice
Outbred Mice

Healthcare By Service (USD Billion, 2025-2035)

Breeding
Cryopreservation
Rederivation
Quarantine
Other services

Healthcare By Technology (USD Billion, 2025-2035)

CRISPR/CAS9
Microinjection
Embryonic Stem Cell Injection
Nuclear Transfer
Other Technologies

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Metabolic Diseases
Immunology
Neurology
Cardiovascular Diseases
Other Therapeutic Diseases

Healthcare By Application (USD Billion, 2025-2035)

Drug Discovery & Development
Research Application
Personalized Medicine

Healthcare By End User (USD Billion, 2025-2035)

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
CROS & CDMOS

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”